Live feed13:00:00·1534dPRReleasevia QuantisnowRubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable TolerabilityByQuantisnow·Wall Street's wire, on your screen.RUBY· Rubius Therapeutics Inc.Health Care
